Eliquis

utilized for stroke prevention to mitigate clotting risks.

Strengths: 2.5 · 5mg

Medicine details

Therapeutic class

Anticoagulant

Pharmacological class

Direct Factor Xa Inhibitor

Precautions and warnings

increased risk of bleeding; discontinue before surgical procedures

Minor side effects

bruising; nosebleed; nausea

Moderate side effects

anaemia; gastrointestinal haemorrhage

Serious side effects

intracranial haemorrhage — requires immediate medical attention

Dosage forms

Film-coated tablet

Administration route

Oral use

Patient summary

utilized for stroke prevention to mitigate clotting risks.

Prescription status

POM

Manufacturer

Bristol-Myers Squibb

Onset Time

1–3 hours

Duration

12 hours

Storage instructions

Store in the original package at room temperature.

Drug interactions

aspirin; clopidogrel; ketoconazole

Age restrictions

Adults only.

Pregnancy and breastfeeding

Pregnancy: Not recommended. Breastfeeding: Not recommended.

Contraindications

hypersensitivity to apixaban; active clinically significant bleeding; hepatic disease associated with coagulopathy

Mechanism of action

Eliquis is an anticoagulant that inhibits factor Xa, a crucial enzyme in the blood coagulation cascade. By blocking this factor, the medication prevents the formation of harmful blood clots, helping reduce the risk of stroke or systemic embolism in patients with specific cardiac conditions.

Eliquis

utilized for stroke prevention to mitigate clotting risks.

Editorial Notes

  • Active ingredient(s): Apixaban
  • Listed indication(s): Venous Thromboembolism, Atrial Fibrillation, Stroke Prevention